🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

18 results for “Eylea” Clear

  1. ABBV-RGX-314 or RGX-314, ABBV-RGX-314 or RGX-314, Lucentis 10 mg/ml solution for injection in pre-filled syringe, Eylea 40 mg/mL solution for injection in pre-filled syringe

    AbbVie Deutschland GmbH & Co. KG

    Neovascular age-related macular degeneration

    phase 3 small molecule active

    1 trial

  2. Aflibercept (EYLEA, BAY86-5321)

    Regeneron UK Limited

    Glaucoma, Neovascular

    phase 3 small molecule completed

    1 trial

  3. Aflibercept (Eylea, BAY 86-5321)

    Regeneron UK Limited

    Glaucoma, Neovascular

    phase 3 small molecule completed

    1 trial

  4. Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

    Regeneron UK Limited

    Macular Edema

    phase 3 mab completed

    1 trial

  5. Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

    Bayer HealthCare AG

    Macular Edema

    phase 3 mab completed

    1 trial

  6. Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

    Regeneron UK Limited

    Macular Degeneration

    phase 3 mab completed

    1 trial

  7. Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)

    Regeneron UK Limited

    Retinal Vein Occlusion

    phase 3 mab completed

    1 trial

  8. Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose

    Regeneron UK Limited

    Macular Edema Secondary to Retinal Vein Occlusion

    phase 3 small molecule completed

    1 trial

  9. DIFLUPREDNATE, Eylea 40 mg/mL solution for injection in pre-filled syringe, Eylea 40 mg/mL solution for injection in pre-filled syringe, 4D-150, Eylea 40 mg/mL solution for injection in pre-filled syringe, Eylea 40 mg/mL solution for injection in pre-filled syringe

    4D Molecular Therapeutics

    Macular neovascularization secondary to age-related macular degeneration (nAMD)

    phase 3 small molecule active

    1 trial

  10. Eylea (Aflibercept, BAY86-5321)

    Regeneron UK Limited

    Retinopathy of Prematurity (ROP)

    phase 3 small molecule completed

    2 trials

  11. Eylea 40 mg/mL solution for injection in a vial

    Lacuna Pharma Pty Ltd

    Retinopathy of prematurity (ROP)

    phase 3 small molecule active

    1 trial

  12. Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)

    Regeneron UK Limited

    Diabetic Macular Edema

    phase 3 small molecule completed

    1 trial

  13. Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)

    Regeneron UK Limited

    Branch Retinal Vein Occlusion

    phase 3 small molecule completed

    1 trial

  14. Aflibercept (BAY86-5321, Eylea)

    Regeneron UK Limited

    Diabetic Macular Edema

    approved small molecule completed

    1 trial

  15. Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

    Regeneron UK Limited

    Neovascular Macular Degeneration

    approved small molecule completed

    1 trial

  16. Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

    Regeneron UK Limited

    Wet Macular Degeneration

    approved small molecule completed

    1 trial

  17. Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)

    Regeneron UK Limited

    Macular Degeneration

    approved small molecule completed

    1 trial

  18. Eylea 114.3 mg/ml solution for injection

    Bayer AG

    Neovascular age-related macular degeneration (nAMD), Diabetic macular edema (DME)

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources